Literature DB >> 6443117

Human in vitro fertilization employing individualized ovulation induction by human menopausal gonadotropins.

N Laufer, A H Decherney, F P Haseltine, M L Polan, B C Tarlatzis, A M Dlugi, F Naftolin.   

Abstract

One hundred six women suffering from obstructive tubal disease not corrected by previous surgery were treated in an in vitro fertilization (IVF) program. Ovulation was induced by 3 amps of human menopausal gonadotropin (HMG)/day starting on the third day of the cycle for 5 days. In most of the patients the regimen was continued for another 1-3 days, depending on the individual's ovarian response (mean, 20 +/- 5 amps/cycle). Monitoring consisted of daily follicular ultrasonography and serum estradiol measurements. Human chorionic gonadotropin (HCG), 10,000 IU, was administered when more than two large (1.5 to 1.8 cm in diameter) follicles were visualized. Using this regimen, a mean of five follicles per woman was aspirated, from which a mean of 3.9 ova was recovered. The oocytes were pre-incubated for 8 or 24 hr, according to the morphological degree of mucification and dispersal of the oocyte-corona-cumulus complex. Following exposure to washed spermatozoa for 16 hr, a 68% fertilization rate was obtained. Oocytes were transferred into the uterus 48 hr after laparoscopy. Ninety-nine transfers (93% of the women) of 1-8 embryos (mean, 2.9/woman) were performed and resulted in 16 clinical pregnancies. No pregnancies occurred in 14 women transferred with one to three oocytes in the pronuclear stage and only one pregnancy (7.1%) was obtained in 14 women transferred with one cleaved oocyte. Over 70% of the women were transferred with two or more cleaved oocytes: in this group the pregnancy/transfer rate was 21%. Of the pregnant women 5 of 16 (31%) aborted between 6 and 10 weeks of gestation and 1 (6%) had an ectopic pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6443117     DOI: 10.1007/bf01129622

Source DB:  PubMed          Journal:  J In Vitro Fert Embryo Transf        ISSN: 0740-7769


  18 in total

1.  A study of factors affecting the success of human fertilization in vitro. I. Influence of ovarian stimulation upon the number and condition of oocytes collected.

Authors:  J Testart; R Frydman; J De Mouzon; B Lassalle; J C Belaisch
Journal:  Biol Reprod       Date:  1983-03       Impact factor: 4.285

2.  On the transfer of conceptuses from oocytes fertilized in vitro.

Authors:  H W Jones; A A Acosta; J E Garcia; B A Sandow; L Veeck
Journal:  Fertil Steril       Date:  1983-02       Impact factor: 7.329

3.  Current problems in human in vitro fertilization and embryo implantation.

Authors:  P L Nayudu; A Lopata; P C Leung; W I Johnston
Journal:  J Exp Zool       Date:  1983-11

4.  The periovulatory and luteal phase of conception cycles following in vitro fertilization and embryo transfer.

Authors:  A M Dlugi; N Laufer; A H DeCherney; N J MacLusky; F P Haseltine; M L Polan; H C Mezer; B Tarlatzis; F Naftolin
Journal:  Fertil Steril       Date:  1984-04       Impact factor: 7.329

5.  The in vivo and in vitro effects of clomiphene citrate on ovulation, fertilization, and development of cultured mouse oocytes.

Authors:  N Laufer; B M Pratt; A H DeCherney; F Naftolin; M Merino; C L Markert
Journal:  Am J Obstet Gynecol       Date:  1983-11-15       Impact factor: 8.661

6.  Pregnancy following intrauterine implantation of an embryo obtained by in vitro fertilization of a preovulatory egg.

Authors:  A Lopata; I W Johnston; I J Hoult; A I Speirs
Journal:  Fertil Steril       Date:  1980-02       Impact factor: 7.329

7.  Incidence of multiple pregnancy after in-vitro fertilisation and embryo transfer.

Authors:  J F Kerin; G M Warnes; P J Quinn; R Jeffrey; C Kirby; C D Matthews; R F Seamark; L W Cox
Journal:  Lancet       Date:  1983-09-03       Impact factor: 79.321

8.  The use of high-dose human menopausal gonadotropin in an in vitro fertilization program.

Authors:  N Laufer; A H DeCherney; F P Haseltine; M L Polan; H C Mezer; A M Dlugi; D Sweeney; F Nero; F Naftolin
Journal:  Fertil Steril       Date:  1983-12       Impact factor: 7.329

9.  Plasma hormones in human gonadotropin induced ovulation.

Authors:  C H Wu
Journal:  Obstet Gynecol       Date:  1977-03       Impact factor: 7.661

10.  The Vienna program of in vitro fertilization and embryo-transfer--a successful clinical treatment.

Authors:  W Feichtinger; P Kemeter; S Szalay
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1983-06       Impact factor: 2.435

View more
  7 in total

1.  The association between chlamydial-specific IgG and IgA antibodies and pregnancy outcome in an in vitro fertilization program.

Authors:  E Lunenfeld; B S Shapiro; B Sarov; I Sarov; V Insler; A H Decherney
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

Review 2.  Drugs used in in vitro fertilisation procedures.

Authors:  I E Messinis
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  [Indications and results of extracorporeal fertilization].

Authors:  K Diedrich
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

4.  The impact of embryo quality on pregnancy outcome in elderly women undergoing in vitro fertilization-embryo transfer (IVF-ET).

Authors:  D Feldberg; J Farhi; D Dicker; J Ashkenazi; M Shelef; J A Goldman
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-10

5.  Super high estradiol response to gonadotropin stimulation in patients undergoing in vitro fertilization.

Authors:  M P Diamond; T Buchholz; S P Boyers; G Lavy; B S Shapiro; A H DeCherney
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-04

6.  The use of synthetic culture medium and patient serum for human in vitro fertilization and embryo replacement.

Authors:  W Feichtinger; P Kemeter; Y Menezo
Journal:  J In Vitro Fert Embryo Transf       Date:  1986-04

7.  Weight of babies conceived in vitro.

Authors:  M P Diamond; G Lavy; J B Russell; S P Boyers; F Nero; A H DeCherney
Journal:  J In Vitro Fert Embryo Transf       Date:  1987-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.